| Literature DB >> 34312578 |
Vikarn Vishwajeet1, Abhishek Purohit1, Deepak Kumar2, Parag Vijayvergia2, Swapnil Tripathi2, Tanuj Kanchan3, Nikhil Kothari4, Naveen Dutt5, Poonam A Elhence1, Pradeep K Bhatia4, Vijaya L Nag6, Mahendra K Garg2, Sanjeev Misra7.
Abstract
AIM: The severe acute respiratory syndrome coronavirus 2 outbreak resulted in severe health impact with the loss of many lives across the world. Pulmonary parenchyma suffers the most from the brunt of the infection. However, evidence suggested a systemic involvement during the course of illness. Information on morphological changes of the liver is sparse in the literature. We aimed to evaluate the pathological findings in the liver by minimally invasive autopsies.Entities:
Keywords: ACE2, Angiotensin-Converting Enzyme 2; ALT, Alanine Aminotransferase; ARDS, Adult Respiratory Distress syndrome; AST, Aspartate Aminotransferase; CBC, Complete Blood Count; CK-MB, Creatine Kinase-MB; COVID-19; COVID-19, Coronavirus Disease 2019; ISH, In situ Hybridization; LDH, Lactate Dehydrogenase; LFTs, Liver Function Tests; PCR, Polymerase Chain Reaction; RNA, Ribonucleic Acid; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; abnormal liver chemistries; autopsy; liver pathology
Year: 2021 PMID: 34312578 PMCID: PMC8294712 DOI: 10.1016/j.jceh.2021.07.004
Source DB: PubMed Journal: J Clin Exp Hepatol ISSN: 0973-6883
Summary of Laboratory Findings.
| Laboratory parameters | Reference range | Median | Interquartile range | Cases with deranged results |
|---|---|---|---|---|
| AST (n = 40) | 7–40 IU/L | 61 | 40–81 | 30 (75%) |
| ALT (n = 40) | 5–35 IU/L | 44.8 | 18–63 | 23 (57.5%) |
| ALP (n = 40) | 40–160 IU/L | 91 | 68–143 | 6 (15%) |
| TB (n=40) | 0.3–1 mg/dl | 0.58 | 0.5–0.77 | 3 (7.5%) |
| LDH (n = 18) | 140–280 IU/L | 529 | 447–667 | 18 (100%) |
| D-dimer (n = 33) | <0.5 ug/ml | 2.8 | 2.03–4.26 | 31 (93.9%) |
| PT (n = 30) | 12–16 s | 14.4 | 13.3–17.7 | 10 (33.3%) |
| APTT (n = 30) | 26–34 s | 33.8 | 29.4–42.3 | 15 (50%) |
| CK-MB (n = 16) | 5–25 IU/L | 27.5 | 23–33 | 10 (62.5%) |
| Sr creatinine (n = 32) | 0.6–1.2 mg/dl | 1.13 | 0.9–1.6 | 14 (43.7%) |
| Sr urea (n = 32) | 15–40 mg/dl | 41 | 27–63 | 16 (50%) |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; TB, total bilirubin; LDH, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; CK-MB, creatine kinase-MB; Sr, serum.
Figure 1(a) Portal tract expansion with mild to moderate degree of portal tract inflammation. (b) Microphotograph shows prominent macrovesicular steatosis. In addition, note the presence of neutrophilic lobular inflammation (encircled area). (c) Intracytoplasmic cholestasis Hematoxylin and eosin stain is used for (a–c); (a-b), 100 x magnification; (c), 400 x magnification.
Figure 2(a) Centrizonal congestion with ischemic hepatocytic loss. (b) Kupffer cell hemophagocytosis (arrow). (c) Sinusoidal influx of neutrophils (arrow). Hematoxylin and eosin stain is used for (a) and (c); periodic acid-Schiff stain is used for (b); (a), 100 x magnification; (b-c), 400 x magnification.
Figure 3(a) Increased number of portal venous channels in portal tracts. Occasional ones are seen herniating into periportal hepatocytes. (b) CD34 highlights these abnormal vascular channels. (c) Sinusoidal microthrombi (encircled areas). Hematoxylin and eosin stain is used for (a) and (c); immunohistochemistry is used for (b); (a-b), 100 x magnification; (c), 400 x magnification.
Histological Findings of the Liver in COVID-19 and Their Correlation With Elevated Liver Enzymes.
| Histological parameters | All cases (n = 41) | Normal AST or ALT N = 8 [I] | AST or ALT 1X-2X (n = 18) [II] | AST or ALT >2X (n = 14) [III] | ||
|---|---|---|---|---|---|---|
| Macrovesicular steatosis | 29 (70.7%) | 8 (100%) | 13 (72.2%) | 8 (57.1%) | 0.080 | 0.051 |
| Mild | 16 (39%) | 3 (37.5%) | 8 (44.4%) | 5 (35.7%) | ||
| Moderate | 11 (26.8%) | 5 (62.5%) | 4 (22.2%) | 2 (14.3%) | ||
| Severe | 2 (4.8%) | 0 | 1 (5.5%) | 1 (7.1%) | ||
| Lobular necroinflammation | 10 (24.4%) | 0 | 5 (27.7%) | 5 (35.7%) | 0.165 | 0.115 |
| Rare individual apoptosis | 8∗ (19.5%) | 1 (12.5%) | 2 (11.1%) | 4 (28.6%) | 1.000 | 0.613 |
| Portal inflammation | 13 (31.7%) | 2 (25%) | 5 (27.7%) | 6 (42.8%) | 1.000 | 0.649 |
| Mild | 11 (26.8%) | 1 (12.5%) | 5 (27.7%) | 5 (35.7%) | ||
| Moderate | 2 (4.8%) | 1 (12.5%) | 0 | 1 (7.1%) | ||
| Severe | 0 | 0 | 0 | 0 | ||
| Fibrosis | 8$& | 2a (25%) | 1b (5.5%) | 5c (35.7%) | 0.649 | 1.000 |
| Centrilobular ischemic necrosis | 11 (26.8%) | 3 (37.5%) | 5 (27.7%) | 3 (21.4%) | 0.660 | 0.624 |
| Cholestasis (all mild) | 17∗ (41.5%) | 5 (62.5%) | 7 (38.9%) | 4 (28.6%) | 0.229 | 0.187 |
| Increased portal vascular channels | 24∗ (58.5%) | 4 (50%) | 10 (55.5%) | 9 (64.3%) | 0.702 | 0.661 |
| Sinusoidal microthrombi | 5∗ (12.2%) | 0 | 3 (16.6%) | 1 (7.1%) | 0.565 | 1.000 |
| Sinusoidal congestion with neutrophil influx | 14 (34.1%) | 1 (12.5%) | 8 (44.4%) | 5 (35.7%) | 0.221 | 0.351 |
| Kupffer cell prominence | 9∗ (21.9%) | 1 (12.5%) | 2# (11.1%) | 5# (35.7%) | 1.000 | 0.351 |
AST, aspartate aminotransferase; AST, alanine aminotransferase.
∗AST/ALT value not available in one case; # includes one case with Kupffer hemophagocytosis; $ includes one case of cirrhosis, three cases with stage 3 fibrosis, and four cases with stage 1 fibrosis (Ishak staging system); & excludes three cases of zone 3 pericellular fibrosis; a represents one case with stage 1 fibrosis and one case with stage 3 fibrosis; b represents one case with stage 3 fibrosis; c represents three cases with stage 1 fibrosis, one case with stage 3 fibrosis, and 1 case with cirrhosis.